

PRIOR AUTHORIZATION POLICY

- POLICY:** Lupus – Benlysta Subcutaneous Prior Authorization Policy
- Benlysta[®] (belimumab subcutaneous injection – Human Genome Sciences/GlaxoSmithKline)

REVIEW DATE: 02/09/2022

OVERVIEW

Benlysta subcutaneous, a B-lymphocyte stimulator-specific inhibitor, is indicated for the following uses:¹

- **Lupus nephritis**, in adults with active disease who are receiving standard therapy.
- **Systemic lupus erythematosus (SLE)**, in patients ≥ 18 years of age with active, autoantibody-positive, systemic disease who are receiving standard therapy.

Benlysta subcutaneous has not been studied and is not recommended in those with severe, active central nervous system lupus, or in combination with other biologics. In some of the clinical trials involving Benlysta, Black patients had a lower response rate for the primary endpoint relative to Black patients receiving placebo; therefore, caution is recommended when considering Benlysta in Black patients. Of note, there is also an intravenous formulation of Benlysta with a similar indication except use is expanded to those ≥ 5 years of age.

Guidelines

Benlysta is addressed in the following guidelines:

- **Lupus Nephritis:** Guidelines for lupus nephritis are available from the European league Against Rheumatism (EULAR) and European Renal Association/European Dialysis and Transplant Association (2019).² Benlysta may be considered as add-on treatment for non-responding/refractory lupus nephritis, to facilitate glucocorticoid sparing, control extra-renal lupus activity, and decrease the risk for extra-renal flares. Guidelines from KDIGO (Kidney Disease: Improving Global Outcomes) [2021] list Benlysta among the therapies recommended for second-line treatment of lupus nephritis.³ The guidelines note that optimal use of Benlysta will become clear as its use increases.
- **SLE:** Guidelines from EULAR (2019) recommend consideration of add-on therapy with Benlysta for patients who have an inadequate response to standard of care (e.g., combinations of hydroxychloroquine and glucocorticoids with or without immunosuppressive agents).⁴ EULAR defines an inadequate response as residual disease activity not allowing tapering of glucocorticoids and/or frequent relapses.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Benlysta subcutaneous. Because of the specialized skills required for evaluation and diagnosis of patients treated with Benlysta subcutaneous as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Benlysta subcutaneous to be prescribed by or in consultation with a physician who specializes in the condition being treated. Approvals are authorized for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Benlysta subcutaneous is recommended in those who meet one of the following criteria:

FDA-Approved Indications

1. **Lupus Nephritis.** Approve for the duration noted if the patient meets ONE of the following (A or B):
 - A) **Initial Therapy.** Approve for 6 months if the patient meets ALL of the following conditions (i, ii, iii, and iv):
 - i) Patient is ≥ 18 years of age; AND
 - ii) Patient has autoantibody-positive systemic lupus erythematosus (SLE), defined as positive for antinuclear antibodies (ANA) and/or anti-double-stranded DNA (anti-dsDNA) antibody; AND
 - iii) Patient meets ONE of the following (a or b):
 - a) The medication is being used concurrently with at least one other standard therapy; OR
Note: Examples of standard therapies include azathioprine, mycophenolate mofetil, cyclophosphamide.
 - b) Patient is determined to be intolerant to standard therapy due to a significant toxicity, as determined by the prescriber; AND
 - iv) The medication is prescribed by or in consultation with a nephrologist or rheumatologist.
 - B) **Patient is Currently Receiving Benlysta Subcutaneous or Intravenous.** Approve for 1 year if the patient meets ALL of the following criteria (i, ii, and iii):
 - i) Patient meets ONE of the following (a or b):
 - a) The medication is being used concurrently with at least one other standard therapy; OR
Note: Examples of standard therapies include azathioprine, mycophenolate mofetil, cyclophosphamide.
 - b) Patient is determined to be intolerant to standard therapy due to a significant toxicity, as determined by the prescriber; AND
 - ii) The medication is prescribed by or in consultation with a nephrologist or rheumatologist; AND
 - iii) Patient has responded to Benlysta subcutaneous or intravenous, as determined by the prescriber.
Note: Examples of a response include improvement in organ dysfunction, reduction in flares, reduction in corticosteroid dose, decrease of anti-dsDNA titer, and improvement in complement levels (i.e., C3, C4).
2. **Systemic Lupus Erythematosus (SLE).** Approve for the duration noted if the patient meets ONE of the following (A or B):
 - A) **Initial Therapy.** Approve for 4 months if the patient meets ALL of the following conditions (i, ii, iii, and iv):
 - i) Patient is ≥ 18 years of age; AND
 - ii) Patient has autoantibody-positive SLE, defined as positive for antinuclear antibodies (ANA) and/or anti-double-stranded DNA (anti-dsDNA) antibody; AND
Note: Not all patients with SLE are positive for anti-dsDNA, but most will be positive for ANA.
 - iii) Patient meets ONE of the following (a or b):
 - a) The medication is being used concurrently with at least one other standard therapy; OR
Note: Examples of standard therapies include an antimalarial (e.g., hydroxychloroquine), systemic corticosteroid (e.g., prednisone), and other immunosuppressants (e.g., azathioprine, mycophenolate mofetil, methotrexate).
 - b) Patient is determined to be intolerant to standard therapy due to a significant toxicity, as determined by the prescriber; AND

- iv) The medication is prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist.
- B) Patient is Currently Receiving Benlysta Subcutaneous or Intravenous.** Approve for 1 year if the patient meets ALL of the following criteria (i, ii, and iii):
- i) Patient meets ONE of the following (a or b):
 - a) The medication is being used concurrently with at least one other standard therapy; OR
Note: Examples of standard therapies include an antimalarial (e.g., hydroxychloroquine), systemic corticosteroid (e.g., prednisone), and other immunosuppressants (e.g., azathioprine, mycophenolate mofetil, methotrexate).
 - b) Patient is determined to be intolerant to standard therapy due to a significant toxicity, as determined by the prescriber; AND
 - ii) The medication is prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist; AND
 - iii) Patient has responded to Benlysta subcutaneous or intravenous, as determined by the prescriber.
Note: Examples of a response include reduction in flares, reduction in corticosteroid dose, decrease of anti-dsDNA titer, improvement in complement levels (i.e., C3, C4), or improvement in specific organ dysfunction (e.g., musculoskeletal, blood, hematologic, vascular, others).

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Benlysta subcutaneous is not recommended in the following situations:

1. **Concurrent Use with Other Biologics.** Benlysta has not been studied and is not recommended in combination with other biologics.¹ Safety and efficacy have not been established with these combinations. See [APPENDIX](#) for examples of other biologics that should not be taken in combination with Benlysta.
2. **Concurrent Use with Lupkynis (voclosporin capsules).** Lupkynis has not been studied in combination with biologics such as Benlysta.¹
3. **Rheumatoid Arthritis.** A Phase II dose-ranging study evaluating patients with rheumatoid arthritis showed only small ACR 20 responses with Benlysta (e.g., ACR 20 response at Week 24 was 28% with Benlysta 10 mg/kg).⁵ Numerous other agents are available with higher ACR responses and established efficacy for rheumatoid arthritis.
4. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Benlysta[®] injection [prescribing information]. Rockville, MD: Human Genome Sciences/GlaxoSmithKline; March 2021.
2. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res (Hoboken)*. 2012;64(6):797-808.
3. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. *Kidney Int*. 2021;100(4):753-779.
4. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78(6):736-745.
5. Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. *J Rheumatol*. 2013;40(5):579-589.
6. Lupkynis[™] capsules [prescribing information]. Rockville, MD: Aurinia; January 2021.

HISTORY

Type of Revision	Summary of Changes	Review Date
Early Annual Revision	Lupus Nephritis: This newly approved condition was added to the policy. For initial therapy the patient must be ≥ 18 years of age. Criteria approve for 6 months for initial therapy (1 year for continuation), if the medication is being used concurrently with at least one other standard therapy unless intolerant. For continuation, the patient must also have also demonstrated a response to initial therapy. For all approvals, Benlysta much be prescribed by or in consultation with a specialist. Conditions Not Recommended for Coverage: Concurrent use with cyclophosphamide intravenous was removed from the Conditions Not Recommended for Coverage (no longer supported in the labeling).	01/20/2021
Annual Revision	Conditions Not Recommended for Approval: Concurrent use with Lupkynis (voclosporin capsules) was added as a condition not recommended for approval.	02/09/2022

APPENDIX

	Mechanism of Action	Examples of Inflammatory Indications*
Biologics		
Saphnelo™ (anifrolumab-fnia IV infusion)	IFN receptor antagonist	SLE
Adalimumab SC Products (Humira®, biosimilars)	Inhibition of TNF	AS, CD, JIA, PsO, PsA, RA, UC
Cimzia® (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, nr-axSpA, PsO, PsA, RA
Etanercept SC Products (Enbrel®, biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA
Infliximab IV Products (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
Simponi®, Simponi® Aria™ (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC IV formulation: AS, PJIA, PsA, RA
Actemra® (tocilizumab IV infusion, tocilizumab SC injection)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA IV formulation: PJIA, RA, SJIA
Kezvara® (sarilumab SC injection)	Inhibition of IL-6	RA
Orencia® (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PsA, RA IV formulation: JIA, PsA, RA
Rituximab IV Products (Rituxan®, biosimilars)	CD20-directed cytolytic antibody	RA
Kineret® (anakinra SC injection)	Inhibition of IL-1	JIA [^] , RA
Stelara® (ustekinumab SC injection, ustekinumab IV infusion)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC IV formulation: CD, UC
Siliq™ (brodalumab SC injection)	Inhibition of IL-17	PsO
Cosentyx® (secukinumab SC injection)	Inhibition of IL-17A	AS, ERA, nr-axSpA, PsO, PsA
Taltz® (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
Ilumya™ (tildrakizumab-asmn SC injection)	Inhibition of IL-23	PsO
Skyrizi® (risankizumab-rzaa SC injection)	Inhibition of IL-23	PsA, PsO
Tremfya™ (guselkumab SC injection)	Inhibition of IL-23	PsO
Entyvio™ (vedolizumab IV infusion)	Integrin receptor antagonist	CD, UC

* Not an all-inclusive list of indication (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; IV – Intravenous; IFN – Interferon; SLE – Systemic lupus erythematosus; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; PJIA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; [^] Off-label use of Kineret in JIA supported in guidelines; ERA – Enthesitis-related arthritis.